Catridecacog

Catridecacog is a recombinant factor XIII A-subunit concentrate used to prevent and treat bleeding episodes in patients with congenital factor XIII A-subunit deficiency. It helps in stabilizing blood clots, thereby reducing the risk of severe bleeding and associated complications.

Indications

- Prevention of bleeding in patients with congenital factor XIII deficiency. - Management of bleeding episodes related to factor XIII deficiency. - Perioperative management in patients with factor XIII deficiency to reduce surgical bleeding risk.

Dosage

- Prophylaxis: Typically, 35 IU/kg body weight administered intravenously every 28 days. - Treatment of bleeding episodes: Dose may be adjusted based on severity; usually a single intravenous infusion to achieve sufficient factor XIII levels. - Dosing should be individualized based on patient response and laboratory monitoring.

Contra-Indications

- Known hypersensitivity to catridecacog or any component of the formulation. - History of severe allergic reactions to other recombinant coagulation factors.

Special Precautions

- Monitor for hypersensitivity reactions during and after infusion. - Use with caution in patients with cardiovascular risk factors due to potential thrombosis risk. - Ensure correct diagnosis of factor XIII deficiency before therapy. - Regular monitoring of factor XIII activity levels is recommended during prophylaxis.

Side Effects

- Common: Headache, dizziness, injection site reactions, nausea, fever. - Rare but serious: Allergic reactions, anaphylaxis, thrombosis.

Drug Interactions

- No major drug interactions reported. - Concomitant use with other procoagulants may increase thrombotic risk.